Clinical team
The paediatric allergist determines eligibility, treatment and monitoring, and manages adverse reactions. Families follow the individual clinical plan.
Professional backgroundSIKALIAS KNOWLEDGE
Allergen preparations: quality and clinical collaboration
An educational framework connecting pharmacy preparation with specialist-led care. Written for pharmacists and healthcare professionals; it is not a formulation, dosing schedule or patient treatment protocol.
Editorial note · Version 1.0 · 11 September 2026
The scope of this work
Sikalias Pharmacy’s experience includes peanut- and pistachio-containing preparations for cases managed by paediatric allergists. This page identifies the questions that must be addressed for an individual preparation. It does not establish that any particular formulation, assay, shelf life or clinical outcome has been validated.
Distinct responsibilities, coordinated communication
Pharmacy laboratory
The responsible pharmacist assesses the preparation request, its technical and legal feasibility, material identity and supporting documentation before accepting it.
Contact the laboratoryQuality questions for each preparation
Identity and traceability
Exact allergen source, supplier, grade, lot and composition; peanut and pistachio are distinct sources and are not treated as interchangeable.
Defined quantities and evidence
The intended quantity and units must be unambiguous. Ingredient weight alone does not establish protein content or biological potency; the required evidence is defined for the preparation.
Consistency and stability
Homogeneity, handling of the dosage form, container compatibility and a formulation-specific basis for storage and use period require assessment.
Cross-contact and controlled records
Allergen cross-contact, cleaning, segregation, labelling, independent checks and traceability must be addressed in the laboratory’s applicable quality system.
Clinical evidence and its boundaries
The EAACI guideline recommends that food-allergen immunotherapy be guided by a clinical team experienced in the treatment and in managing adverse effects and anaphylaxis. Desensitisation and lasting remission are distinct outcomes. Evidence for one allergen or product does not validate a different preparation.
EAACI guideline · recommendations 8–9 and outcome definitionsStart a professional conversation
Do not attempt allergen preparation or treatment changes using information from this page. Preparation enquiries are handled between healthcare professionals; do not send patient identifiers in a first email.
Professional enquiry: lab@sikalias.grEditorial identity
Editorial author: Stasinos Chr. Sikalias, pharmacist. Educational overview, version 1.0, 11 September 2026. The clinical reference supports the general context; it is not evidence of efficacy for Sikalias preparations.